Breaking News, Collaborations & Alliances

Stallergenes, DBV in Allergy R&D Pact

Will use DBV's Viaskin epicutaneous delivery technology

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Stallergenes S.A. and DBV Technologies have entered an R&D agreement for the treatment of birch allergy. The partnership will combine Stallergenes’ respiratory expertise with DBV’s Viaskin epicutaneous delivery technology that modulates the immune response to allergens. In conjunction with the agreement, Stallergenes will acquire 2% equity in DBV from existing shareholders.   Stallergenes will fund DBV’s preclinical development, which aims to deliver a clinical product cand...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters